CLLS

0.92096.39%
LA

Laurent Arthaud

Director

Mr. Laurent Arthaud serves as a Deputy Chief Executive Officer and General Partner at Fonds d'amorçage biothérapies innovantes et maladies rares, FCPR. Mr. Arthaud is responsible for investments in biotechnology field. Mr. Arthaud has been the Managing Director of Life Sciences and Ecotechnologies at Bpifrance Investissement (formerly CDC Enterprises) since 2012. He served as President of Board of Directors of SparingVision SAS until January 2020 and serves as its Director. Mr. Arthaud served as a Vice President at Aventis Capital from 1999 to 2004. He has been Director of Calyxt, Inc. since July 6, 2020. He serves as Director of ENYO Pharma SAS since 2019 and Aledia and Ribogenics, Inc. He was in charge of the venture capital activities of the pharmaceutical Aventis. He serves as Deputy Chief Executive Officer at InnoBio, FCPR. He joined Arthaud in 2006. He served as President of Pharmavent Partners from 2004 to 2006. Mr. Arthaud served as Deputy Chief Executive Officer at CDC Enterprises from 2006 to 2012. He served as Managing Partner at Pharmavent Partners from 2004 to 2006. In 1995, he served as a Technical Advisor in charge of workforce and unemployment matters at the French Prime Minister Alain Juppé Cabinet. He was employed at the Forecasts Department of the French Ministry of Finance. Mr. Arthaud started his career in 1986 at the INSEE, French Economic Statistics Institute. He serves as a Board Observer of Sangamo Therapeutics France S.A.S. (formerly known as TxCell S.A.). (TxCell Promesses). He served as a Director at Urogene, S.A. Mr. Arthaud serves as Member of Supervisory Board at Apovia AG. He serves as a Director of InnoBio, FCPR. Since 2009, he has also directed InnoBio, an investment fund managed by Bpifrance Investissement as part of the FSI France Investissement program. He was Director of Adocia SA since October 24, 2010 until 2022. He serves as a Member of the Supervisory Board at Aventis S.A. He serves as Director at Cellectis S.A. since October 2023. He served as Director of Cellectis S.A and served as its Independent Director until October 2023. He previously served as Director at Calyxt, Inc. since July 2017 until May 17, 2019. He serves as Director at Kurma Life Sciences Partners, TxCell, Adocia and Sparinvision SAS. He served as Director of Emertee Gestion from 2006 to 2016. He served as an Independent Director of Cellectis S.A. since October 28, 2011. From April 2007 to June 4, 2015. He served as a Director of Sangamo Therapeutics France S.A.S. (formerly known as TxCell S.A.). (TxCell Promesses) from 2012 to 2018. He served as a Non-Employee Director at Scynexis, Inc. since April 2007 until June 4, 2015 served as its a Director until March 2006. He served as a Director at Aventis Venture Activities. He served as a Director of Genavent, FCPR and IntegraGen S.A. Mr. Arthaud graduated from Ecole Polytechnique (Engineering School) and from Ecole Nationale de Statistique et d'Administration Economique (School for Statistics and Economics), Paris, France.

公司职务